Merck & Co. Inc. (NYSE:MRK) Signs Research Deal

Merck & Co. Inc. (NYSE:MRK) and AbD Serotec have signed a license agreement for
use of HuCAL GOLD in vaccine research. Merck & Co. Inc. (NYSE:MRK) Signs
Research Deal Merck & Co. Inc. (NYSE:MRK) and MorphoSys AG's research and
diagnostic antibody unit AbD Serotec have signed a license accord for use of
MorphoSys AG's HuCAL GOLD in Vaccine Research. According to the contract,
Merck & Co. Inc. (NYSE:MRK) has granted access to HuCAL GOLD for research
purposes, with the choice to improve to MorphoSyss latest proprietary antibody
library HuCAL PLATINUM. MorphoSyss research and diagnostic antibody segment AbD
Serotec will receive annual user fees from Merck & Co. Inc. (NYSE:MRK) for
access to the HuCAL technology and license fees for clinical monitoring
reagents. Merck & Co. Inc. (NYSE:MRK) stocks are currently standing at 33.44.
Price History Last Price: 33.44 52 Week Low / High: 31.06 / 37.68 50 Day Moving
Average: 35.74 6 Month Price Change %: 3.2% 12 Month Price Change %: -2.7%